COVID-19 Induced Immunosuppression resulting in Pulmonary Mucormycosis : A Long COVID sequalae

Authors

  • Dhruv Talwar Post Graduate Resident, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India
  • Sunil Kumar Professor, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India
  • Sourya Acharya Professor and Head of Department, Department of Medicine,Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India
  • Sparsh Madaan Post Graduate Resident, Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra,India 442001
  • Vidyashree Hulkoti Post Graduate Resident, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India

DOI:

https://doi.org/10.3329/jom.v22i2.56707

Keywords:

Pulmonary Mucormycosis, Long Covid, Immunosuppression

Abstract

With increasing incidence of Severe Acute Respiratory Distress Virus 2(SARS -CoV -2) in India, there has been growing reports of super infections in post covid 19 period. Long COVID refers to persistence of COVID19 symptoms for weeks to months. While most common manifestation of long COVID is fatigue and ill health, it may lead to development of life-threatening complications like Pulmonary Mucormycosis. We report a case of 54 year young, non-diabetic previously healthy male who had moderate COVID19 treated with low dose steroids and recovered completely, only to present with hemoptysis 3 months later on High Resolution Computed Tomography Scan of the Chest and Rhizopus fungi on bronchoalveolar lavage confirming Post Covid Pulmonary Mucormycosis in non-immunocompromised host. Patient was managed with dual antifungal therapy intravenous Liposomal Amphotericin B and Posaconazole for 3 weeks, followed by oral Posaconazole.

J MEDICINE 2021; 22: 150-154

Downloads

Download data is not yet available.
Abstract
264
PDF
215

Downloads

Published

2021-12-01

How to Cite

Talwar, D. ., Kumar, S. ., Acharya, S. ., Madaan, S. ., & Hulkoti, V. . (2021). COVID-19 Induced Immunosuppression resulting in Pulmonary Mucormycosis : A Long COVID sequalae. Journal of Medicine, 22(2), 150–154. https://doi.org/10.3329/jom.v22i2.56707

Issue

Section

Case Reports